Q-omics provides the consensus-scored PTMAP9 profile across patient tissues and cancer cell-line models. PTMAP9 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PTMAP9 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, PTMAP9 RNA expression shows 17,977 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and COAD as cancer lineages where PTMAP9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTMAP9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTMAP9 survival associations across molecular data types. PTMAP9 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTMAP9 RNA expression–survival associations across cancer types. High PTMAP9 expression shows unfavorable associations in ACC, LUAD and LGG, but favorable associations in BLCA, COAD and THCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PTMAP9 RNA expression.
This table summarizes PTMAP9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for PTMAP9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTMAP9 shows lower tumor expression in KICH and higher tumor expression in COAD, STAD, HNSC, LIHC and LUAD. The COAD box plot shows higher PTMAP9 RNA expression in tumor versus normal tissue (log2 FC = +1.894, t-test p < 0.001).
This table shows molecular features associated with PTMAP9 in patient tissues and cancer cell lines. In patient samples, PTMAP9 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PTMAP9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC.
